Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Executive Medical Director
CONTACT
Lead
Ray Therapeutics, Inc.
In this Phase 2/3, double-masked study, approximately 60 eligible participants with RP will be enrolled and randomized to receive in the study eye either a single, unilateral intravitreal injection of lower dose RTx-015, higher dose RTx-015, or a sham injection. Participants who meet all eligibility criteria will be randomized in a 1:1:1 ratio. Participants will be followed for a total of 12 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted